ATE526056T1 - Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes - Google Patents

Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes

Info

Publication number
ATE526056T1
ATE526056T1 AT03790946T AT03790946T ATE526056T1 AT E526056 T1 ATE526056 T1 AT E526056T1 AT 03790946 T AT03790946 T AT 03790946T AT 03790946 T AT03790946 T AT 03790946T AT E526056 T1 ATE526056 T1 AT E526056T1
Authority
AT
Austria
Prior art keywords
diabetes
type
igf
peptide
tolerogenic treatment
Prior art date
Application number
AT03790946T
Other languages
English (en)
Inventor
Vincent Geenen
Original Assignee
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liege filed Critical Univ Liege
Application granted granted Critical
Publication of ATE526056T1 publication Critical patent/ATE526056T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03790946T 2002-08-30 2003-08-28 Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes ATE526056T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40727302P 2002-08-30 2002-08-30
US43229502P 2002-12-09 2002-12-09
US43802903P 2003-01-02 2003-01-02
PCT/EP2003/009623 WO2004019965A2 (en) 2002-08-30 2003-08-28 Thymus-based tolerogenic approaches for type i diabetes.

Publications (1)

Publication Number Publication Date
ATE526056T1 true ATE526056T1 (de) 2011-10-15

Family

ID=31982346

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03790946T ATE526056T1 (de) 2002-08-30 2003-08-28 Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes

Country Status (7)

Country Link
US (1) US20040138116A1 (de)
EP (1) EP1536826B1 (de)
JP (1) JP2006509033A (de)
AT (1) ATE526056T1 (de)
AU (1) AU2003266331B2 (de)
CA (1) CA2496692A1 (de)
WO (1) WO2004019965A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006052844A2 (en) * 2004-11-04 2006-05-18 Medical College Of Georgia Research Institute Tolerogenic vaccine and method
GB0426644D0 (en) * 2004-12-03 2005-01-05 Univ Aberdeen T-cell modulation
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
DK1971361T3 (da) * 2005-12-23 2014-09-08 James D Kelly Forbedrede glycoformer af thyroidstimulerende hormonreceptor-polypeptidagonist til behandling af metabolisk syndrom
IL247927B (en) 2014-05-07 2022-09-01 Boehringer Ingelheim Int Container, a device that turns a liquid into a fine spray and use
EP4212547A1 (de) 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Modifizierte chimäre rezeptoren und zugehörige zusammensetzungen und verfahren
CN108114271B (zh) * 2016-11-29 2021-07-02 中国科学院上海营养与健康研究所 含胰岛素样生长因子-2的药物组合物及其应用
WO2018189661A2 (en) * 2017-04-10 2018-10-18 Palti Yoram Prof Methods and compounds for treating diabetes
US20230001010A1 (en) * 2019-07-19 2023-01-05 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
KR20230090336A (ko) 2020-10-13 2023-06-21 베타바이브 리미티드 당뇨병 및 관련된 대사성 질환을 치료하기 위한 방법 및 화합물
MX2024004398A (es) 2021-10-12 2024-07-09 Betavive Ltd Peptidos y fragmentos para tratar diabetes y enfermedades metabolicas asociadas.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU613876B2 (en) * 1986-10-01 1991-08-15 Merck & Co., Inc. Synthetic genes encoding proteins from plasmid containing eucaryotic secretory signal peptides and process for secreting encoded proteins
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
NL9102009A (nl) * 1991-11-29 1993-06-16 Stichting Katholieke Univ Produktie van bioactieve peptiden met recombinante cellen.
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1999042482A1 (en) * 1998-02-23 1999-08-26 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
DE60120372T2 (de) * 2000-03-24 2007-07-05 Genentech Inc., San Francisco Verwendung von insulin zur behandlung von knorpelkrankheiten

Also Published As

Publication number Publication date
JP2006509033A (ja) 2006-03-16
AU2003266331B2 (en) 2008-08-07
EP1536826A2 (de) 2005-06-08
CA2496692A1 (en) 2004-03-11
WO2004019965A3 (en) 2004-04-22
EP1536826B1 (de) 2011-09-28
AU2003266331A1 (en) 2004-03-19
WO2004019965A2 (en) 2004-03-11
US20040138116A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
CY1108563T1 (el) Μεθοδοι και υλικα για τη θεραπεια της ανεπαρκειας (ελλειψης) τεστοστερονης στους ανδρες
ZA200702322B (en) Compositions and methods for the diagnosis and treatment of tumor
DE602005012276D1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
NZ593815A (en) Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
CY1112487T1 (el) Βραχειας-δρασης ηρεμιστικοι υπνωτικοι παραγοντες για αναισθησια και καταστολη
EP2166845A4 (de) Alpha-connexin-c-terminale (act) peptide für die behandlung der altersbedingten makulardegeneration
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
DE502006007963D1 (de) Verwendung von hydrophobinen zur schmutzabweisenden behandlung von harten oberflächen
SI1546182T1 (sl) Sestavki in postopki za diagnozo in zdravljenje tumorja
HRP20080617T3 (en) Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
ATE457736T1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
ATE427956T1 (de) Ckrox-peptide und ihre analoge zur behandlung von hautalterung
ATE361914T1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
ATE475670T1 (de) Konsensus-peptid
DE602004005821D1 (de) Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties